261 related articles for article (PubMed ID: 14661365)
1. [A new strategy for monitoring levels of cyclosporin A in the blood of patients after kidney transplantation].
Halacová M; Jedlicková B; Průsa R
Ceska Slov Farm; 2003 Nov; 52(6):267-71. PubMed ID: 14661365
[TBL] [Abstract][Full Text] [Related]
2. Long-term comparative results of C0 and C2 monitoring of CyA in renal transplanted patients.
Paydaş S; Balal M; Sertdemir Y; Seyrek N; Karayaylali I
Ren Fail; 2005; 27(4):409-13. PubMed ID: 16060128
[TBL] [Abstract][Full Text] [Related]
3. Evolution of the therapeutic drug monitoring of cyclosporine.
Citterio F
Transplant Proc; 2004 Mar; 36(2 Suppl):420S-425S. PubMed ID: 15041378
[TBL] [Abstract][Full Text] [Related]
4. A randomized, prospective, pharmacoeconomic trial of neoral 2-hour postdose concentration monitoring versus tacrolimus trough concentration monitoring in de novo liver transplant recipients.
Shenoy S; Hardinger KL; Crippin J; Korenblat K; Lisker-Melman M; Lowell JA; Chapman W
Liver Transpl; 2008 Feb; 14(2):173-80. PubMed ID: 18236391
[TBL] [Abstract][Full Text] [Related]
5. Advantages of C2 monitoring to avoid acute rejection in pediatric heart transplant recipients.
Schubert S; Abdul-Khaliq H; Lehmkuhl HB; Hübler M; Abd El Rahman MY; Miera O; Ewert P; Weng Y; Wei H; Krüdewagen B; Hetzer R; Berger F
J Heart Lung Transplant; 2006 Jun; 25(6):619-25. PubMed ID: 16730566
[TBL] [Abstract][Full Text] [Related]
6. Study of cyclosporine level at 2 hours after administration in preoperative kidney transplant recipients for prediction of postoperative optimal cyclosporine dose.
Sukhavasharin N; Praditpornsilpa K; Avihingsanon Y; Kuoatawintu P; O-Charoen R; Kansanabuch T; Tungsanga K; Eiam-Ong S
J Med Assoc Thai; 2006 Aug; 89 Suppl 2():S15-20. PubMed ID: 17044449
[TBL] [Abstract][Full Text] [Related]
7. Correlation of C0 and C2 levels with cyclosporine side effects in kidney transplantation.
Rodrigo E; Ruiz JC; Angeles de Cos M; Ruiz J; Gago M; Piñera C; Sánchez B; González-Cotorruelo J; Gómez-Alamillo C; Arias M
Transplant Proc; 2009; 41(6):2328-31. PubMed ID: 19715910
[TBL] [Abstract][Full Text] [Related]
8. C2 is an age-independent parameter for optimal cyclosporine exposure in long-term kidney transplant recipients.
Ferraresso M; Citterio F; Ghio L; Romagnoli J; Edefonti A; Berardinelli L; Castagneto M
Transplant Proc; 2004 Nov; 36(9):2656-8. PubMed ID: 15621115
[TBL] [Abstract][Full Text] [Related]
9. Enhanced clinical utility of de novo cyclosporine C2 monitoring after lung transplantation.
Morton JM; Aboyoun CL; Malouf MA; Plit ML; Glanville AR
J Heart Lung Transplant; 2004 Sep; 23(9):1035-9. PubMed ID: 15454168
[TBL] [Abstract][Full Text] [Related]
10. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
Dösch AO; Ehlermann P; Koch A; Remppis A; Katus HA; Dengler TJ
Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
[TBL] [Abstract][Full Text] [Related]
11. Blood cyclosporine level soon after kidney transplantation is a major determinant of rejection: insights from the Mycophenolate Steroid-Sparing Trial.
Gotti E; Perico N; Gaspari F; Cattaneo D; Lesti MD; Ruggenenti P; Segoloni G; Salvadori M; Rigotti P; Valente U; Donati D; Sandrini S; Federico S; Sparacino V; Mourad G; Bosmans JL; Dimitrov BD; Iordache BE; Remuzzi G
Transplant Proc; 2005 Jun; 37(5):2037-40. PubMed ID: 15964332
[TBL] [Abstract][Full Text] [Related]
12. C2 and C0 values for monitoring cyclosporine therapy in stable heart transplant recipients.
Diciolla F; Scolletta S; Berti L; Maccherini M; Federici D; Bernazzali S; Lisi G; Chiavarelli M
Transplant Proc; 2005 Mar; 37(2):1355-9. PubMed ID: 15848719
[TBL] [Abstract][Full Text] [Related]
13. Calcineurin Inhibitor Determination in Whole Blood With the RXL Dimension Analyzer: A Useful Tool for Immunosuppressive Drug Monitoring.
Ventura E; Bonardet A; Pageaux GP; Mourad G; Cristol JP
Transplant Proc; 2009 Mar; 41(2):707-9. PubMed ID: 19328963
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic monitoring of cyclosporine in kidney transplantation: the Halifax experience.
Singh D; Kiberd B; Belitsky P; Fraser A; Balbontin F; Lawen J
Transplant Proc; 2004 Mar; 36(2 Suppl):414S-419S. PubMed ID: 15041377
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic drug monitoring of cyclosporine.
Midtvedt K
Transplant Proc; 2004 Mar; 36(2 Suppl):430S-433S. PubMed ID: 15041380
[TBL] [Abstract][Full Text] [Related]
16. Cyclosporine C2 monitoring improves renal dysfunction after lung transplantation.
Glanville AR; Morton JM; Aboyoun CL; Plit ML; Malouf MA
J Heart Lung Transplant; 2004 Oct; 23(10):1170-4. PubMed ID: 15477111
[TBL] [Abstract][Full Text] [Related]
17. Graft function based on two hours peak level monitoring of cyclosporine A during the first six months of renal transplantation.
Hami M; Naghibi M; Mojahedi MJ; Sharifipour F; Shakeri MT
Saudi J Kidney Dis Transpl; 2012 Nov; 23(6):1169-74. PubMed ID: 23168844
[TBL] [Abstract][Full Text] [Related]
18. Early cyclosporine C0 and C2 monitoring in de novo kidney transplant patients: a prospective randomized single-center pilot study.
Kyllönen LE; Salmela KT
Transplantation; 2006 Apr; 81(7):1010-5. PubMed ID: 16612277
[TBL] [Abstract][Full Text] [Related]
19. Cyclosporine C2 target levels and acute cellular rejection after lung transplantation.
Glanville AR; Aboyoun CL; Morton JM; Plit M; Malouf MA
J Heart Lung Transplant; 2006 Aug; 25(8):928-34. PubMed ID: 16890113
[TBL] [Abstract][Full Text] [Related]
20. Impact of late conversion from C0 to C2 monitoring of microemulsified cyclosporine in pediatric living donor liver transplant recipients.
Takatsuki M; Chen CL; Chen YS; Wang CC; Lin CC; Yang CH; Yong CC; Liu YW
Clin Transplant; 2004 Dec; 18(6):694-9. PubMed ID: 15516246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
